Should a continuous intravenous nitroglycerin infusion be started in the pre‑operative area before the patient goes to the operating room?

Prophylactic Continuous IV Nitroglycerin Before Surgery: Not Recommended

Prophylactic intravenous nitroglycerin should NOT be routinely started as a continuous drip in the pre-operative area before noncardiac surgery. The evidence consistently shows no benefit in reducing myocardial ischemia, MI, or cardiac death, while posing significant hemodynamic risks 1, 2, 3, 4.

Evidence-Based Recommendation

The most recent and authoritative guideline—the 2014 ACC/AHA Perioperative Guidelines—gives prophylactic intravenous nitroglycerin a Class III: No Benefit recommendation, stating it is "not effective in reducing myocardial ischemia in patients undergoing noncardiac surgery" 4. This represents the strongest evidence against routine prophylactic use.

Multiple earlier ACC/AHA perioperative guidelines (2007,2009) consistently classified prophylactic intraoperative nitroglycerin as Class IIb (usefulness unclear), emphasizing that:

• It may have no effects or actually lead to cardiovascular decompensation through preload reduction 2, 3
• Only 1 of 4 controlled studies showed reduced intraoperative ischemia (in carotid endarterectomy patients)
• Neither of the 2 small noncardiac surgery studies demonstrated reduction in MI or cardiac death 2

Research Evidence Confirms Lack of Benefit

A 2017 meta-analysis of 10 trials (353 patients) found prophylactic IV nitroglycerin did not significantly decrease intraoperative MI (RR=0.61; 95% CI: 0.33-1.13; p=0.12) 5. Trial sequential analysis showed only 9.5% of required information was achieved, but the trend remained non-significant.

A 1993 randomized trial in high-risk noncardiac surgery patients found no difference in perioperative ischemia between nitroglycerin (0.9 mcg/kg/min) and control groups (30% vs 32% incidence) 6. Importantly, most ischemia occurred during emergence from anesthesia and was associated with acute heart rate increases—mechanisms that nitroglycerin does not address.

When Nitroglycerin IS Indicated

Nitroglycerin has clear roles in specific acute cardiac conditions, not prophylaxis:

Acute Heart Failure/Pulmonary Edema

• Recommended for acute heart failure with SBP >110 mmHg 7
• Start at 10-20 mcg/min IV, titrate by 5-10 mcg/min every 3-5 minutes 7
• Avoid if SBP <90 mmHg 7

Unstable Angina/NSTEMI

• Recommended for first 24-48 hours in patients with CHF, large anterior infarction, persistent ischemia, or hypertension 8, 9, 10
• Start at 10 mcg/min, increase by 10 mcg/min every 3-5 minutes until symptom relief or blood pressure response 8, 10
• Ceiling dose typically 200 mcg/min 8, 10

Intraoperative Treatment (Not Prophylaxis)

• Nitroglycerin can reverse active myocardial ischemia when it occurs intraoperatively 2
• Should be used reactively based on hemodynamic monitoring and clinical signs

Critical Safety Concerns

Starting prophylactic nitroglycerin preoperatively creates multiple hazards:

Hemodynamic Instability:

• Vasodilation and decreased preload can cause significant hypotension 2, 3
• Anesthetic agents mimic nitroglycerin's vasodilating effects, potentially causing severe hypotension when combined 2
• Hypotension may be accompanied by paradoxical bradycardia and increased angina 11

Volume Status Considerations:

• Patients must have adequate intravascular volume before nitroglycerin administration 2
• Hypovolemia combined with nitroglycerin can lead to cardiovascular decompensation 2, 3

Drug Interactions:

• Interferes with heparin anticoagulation—requires frequent aPTT monitoring if used 11
• Contraindicated within 24 hours of sildenafil or 48 hours of tadalafil 8, 10

Specific Clinical Scenarios

For patients with stable angina on chronic nitrates:

• Continue their home oral/topical nitrate regimen perioperatively 8, 10
• Do NOT convert to prophylactic IV infusion unless acute ischemia develops

For patients with recent unstable angina:

• If already on IV nitroglycerin for active symptoms, this may be continued into the OR
• This represents treatment of ongoing ischemia, not prophylaxis
• Requires careful hemodynamic monitoring and coordination with anesthesia team 1, 2

For cardiac surgery (CABG):

• A 2004 study of 3,976 CABG patients found preoperative IV nitroglycerin had no effect on mortality, MI, or balloon pump use after propensity matching 12
• A 2018 network meta-analysis favored diltiazem over nitroglycerin for CABG, with nitroglycerin associated with higher postoperative atrial fibrillation rates 13

Common Pitfalls to Avoid

1. Do not start prophylactic IV nitroglycerin "just in case" in high-risk patients—it provides no benefit and adds risk
2. Do not confuse treatment of active ischemia/heart failure (appropriate indication) with prophylaxis (not indicated)
3. Do not assume nitroglycerin prevents ischemia caused by tachycardia and increased oxygen demand during emergence—it doesn't address these mechanisms 6
4. Do not start nitroglycerin without ensuring adequate volume status and understanding the anesthetic plan 2

Alternative Perioperative Strategies

Instead of prophylactic nitroglycerin, focus on evidence-based interventions:

• Beta-blockers: Continue in patients already taking them; consider initiation in high-risk vascular surgery patients 1, 4
• Statins: Continue perioperatively; consider initiation ≥2 weeks before vascular surgery 1, 4, 14
• Adequate analgesia and hemodynamic control to prevent tachycardia and hypertension during emergence 2